Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study

Parmar, 2021, Pharmaceutical nanocrystals: a promising approach for improved topical drug delivery, Drug Discov. Today, 27, 1236 Wenlock, 2013, In silico physicochemical parameter predictions, Mol. Pharm., 10, 1224, 10.1021/mp300537k Zarmpi, 2020, Biopharmaceutical understanding of excipient variability on drug apparent solubility based on drug physicochemical properties: case study—hypromellose (HPMC), AAPS J., 22, 1 Xu, 2021, An investigation on the effect of drug physicochemical properties on the enhancement strength of enhancer: the role of drug-skin-enhancer interactions, Int. J. Pharm., 607, 10.1016/j.ijpharm.2021.120945 Williams, 2013, Strategies to address low drug solubility in discovery and development, Pharmacol. Rev., 65, 315, 10.1124/pr.112.005660 Byrn, 2010, Accelerating proof of concept for small molecule drugs using solid-state chemistry, J. Pharm. Sci., 99, 3665, 10.1002/jps.22215 Mannully, 2019, Lipid modification of staphylokinase and its implications on stability and activity, Int. J. Boil. Macromol., 121, 1037, 10.1016/j.ijbiomac.2018.10.134 Di, 2009, Drug-like property concepts in pharmaceutical design, Curr. Pharm. Des., 15, 2184, 10.2174/138161209788682479 Amidon, 1995, A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 10.1023/A:1016212804288 Maghsoodi, 2020, Rational selection of formulation components to improve dissolution of dipyridamole, J. Drug Deliv. Sci. Technol., 55 Stocker, 2020, Spray encapsulation as a formulation strategy for drug-based room temperature ionic liquids: exploiting drug-polymer immiscibility to enable processing for solid dosage forms, Mol. Pharm., 17, 3412, 10.1021/acs.molpharmaceut.0c00467 Zhang, 2015, From a binary salt to salt co-crystals of antibacterial agent lomefloxacin with improved solubility and bioavailability, Acta Crystallogr. B, 71, 437, 10.1107/S2052520615011191 Skieneh, 2017, Co-amorphous form of curcumin–folic acid dihydrate with increased dissolution rate, Cryst. Growth Des., 17, 6273, 10.1021/acs.cgd.7b00947 Khadka, 2021, Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats, Eur. J. Pharm. Biopharm., 162, 1, 10.1016/j.ejpb.2021.02.011 Emer, 2021, Design and characterisation of an amorphous formulation of nifedipine for the treatment of autonomic dysreflexia, J. Phar. Pharmacol., 73, 928, 10.1093/jpp/rgab034 Sapkal, 2018, Solid dispersion of valsartan for solubility improvement using betacyclodextrin, MOJ Bioequiv. Availab., 5, 313 Medarević, 2018, Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: in vitro-in silico approach, Eur. J. Pharm. Sci., 124, 188, 10.1016/j.ejps.2018.08.026 Ueda, 2019, Molecular mobility suppression of ibuprofen-rich amorphous nanodroplets by HPMC revealed by NMR relaxometry and its significance with respect to crystallization inhibition, Mol. Pharmaceutics, 16, 4968, 10.1021/acs.molpharmaceut.9b00840 Hoppu, 2009, Rheology and molecular mobility of amorphous blends of citric acid and paracetamol, Eur. J. Pharm. Biopharm., 71, 55, 10.1016/j.ejpb.2008.06.029 Dengale, 2016, Recent advances in co-amorphous drug formulations, Adv. Drug Deliv. Rev., 100, 116, 10.1016/j.addr.2015.12.009 Wang, 2022, Platensimycin-berberine chloride co-amorphous drug system: Sustained release and prolonged half-life, Eur. J. Pharm. Biopharm., 179, 126, 10.1016/j.ejpb.2022.09.002 Kim, 2008, Translational therapeutics of dipyridamole, Arterioscler. Thromb. Vasc. Biol., 28, s39, 10.1161/ATVBAHA.107.160226 El-Sisi, 2020, Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid ehrlich carcinoma-bearing mice, Naunyn Schmiedebergs Arch. Pharmacol., 383, 1113, 10.1007/s00210-019-01803-2 Thomé, 2019, Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells, Exp. Cell Res., 382, 10.1016/j.yexcr.2019.06.001 Guo, 2010, Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells, Cerebrovasc. Dis., 30, 290, 10.1159/000319072 Terhaag, 1986, The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison, Int. J. Clin. Pharmacol. Ther. Toxicol., 24, 298 Russell, 1994, pH-related changes in the absorption of dipyridamole in the elderly, Pharm. Res., 11, 136, 10.1023/A:1018918316253 Vepuri, 2016, Synthesis, characterization and molecular modelling of a novel dipyridamole supramolecule – X-ray structure, quantum mechanics and molecular dynamics study to comprehend the hydrogen bond structure-activity relationship, J. Mol. Struct., 1105, 194, 10.1016/j.molstruc.2015.10.050 Baghel, 2018, An investigation into the solid-state properties and dissolution profile of spray dried ternary amorphous solid dispersions: a rational step towards the design and development of multi-component amorphous system, Mol. Pharm., 15, 3796, 10.1021/acs.molpharmaceut.8b00306 Sanganwar, 2009, Nano-mixing of dipyridamole drug and excipient nanoparticles by sonication in liquid CO2, Powder Technol., 196, 36, 10.1016/j.powtec.2009.06.015 Xi, 2019, Development and evaluation of dipyridamole sustained release tablets containing micro-environmental pH modifiers, J. Drug Deliv. Sci. Technol., 54 Ricevuti, 1991, Pharmacokinetics of dipyridamole-beta-cyclodextrin complex in healthy volunteers after single and multiple doses, Eur. J. Drug Metab. Pharmacokinet., 16, 197, 10.1007/BF03189959 Kostenbauder, 2010, Formation of molecular complexes by some water-soluble amides interaction of several amides with p-hydroxybenzoic acid, salicylic acid, chloramphenicol, and phenol, J. Phar. Sci., 45, 518, 10.1002/jps.3030450804 Sun, 2022, Evaluation of kinetic stability of dipyridamole amorphous drug system, J. Shihezi U. (Natural Science), 40, 21 M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, G.A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino, B.G. Janesko, R. Gomperts, B. Mennucci, H.P. Hratchian, J.V. Ortiz, A.F. Izmaylov, J.L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V.G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. LiangM. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J.J.A. Montgomery, J.E. Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, J.M.illam, M. Klene, C. Adamo, R. Cammi, J.W. Ochterski, R.L. Martin, K. Morokuma, O. Farkas, J.B. Foresman, D.J. Fox, Gaussian 09, Revision A. 02 (2016) Gaussian, Inc.: Wallingford CT. Dedroog, 2019, Solid-state analysis of amorphous solid dispersions: why DSC and XRPD may not be regarded as stand-alone techniques, J. Pharm. Biomed. Anal., 178 Berbenni, 2002, Thermoanalytical and spectroscopic characterization of solid state dipyridamole, J. Therm. Anal. Calorim., 68, 413, 10.1023/A:1016075332451 Kumar, 2017, Pharmaceutical cocrystals: an overview, Indian J. Pharm. Sci., 79, 858, 10.4172/pharmaceutical-sciences.1000302 Shi, 2020, Ibrutinib and carboxylic acid co-amorphous system with increased solubility and dissolution: a potential interaction mechanism, J. Drug Deliv. Sci. Tec., 59 Cruz-Cabeza, 2012, Acid–base crystalline complexes and the pKa rule, CrystEngComm., 14, 6362, 10.1039/c2ce26055g Liu, 2020, Determination of the optimal molar ratio in amino acid-based co-amorphous systems, Mol. Pharm., 17, 1335, 10.1021/acs.molpharmaceut.0c00042 Ueda, 2018, Application of a salt coformer in a co-Amorphous drug system dramatically enhances the glass transition temperature: a case study of the ternary system carbamazepine, citric acid, and L-arginine, Mol. Pharm., 15, 2036, 10.1021/acs.molpharmaceut.8b00174 Fox, 1956, Influence of diluent and of copolymer composition on the glass temperature of a polymer system, Bull. Am. Phys. Soc., 1, 123 Sakka, 1971, Relation between apparent glass transition temperature and liquids temperature for inorganic glasses, J. Non Cryst. Solids, 6, 145, 10.1016/0022-3093(71)90053-6 Braun, 2012, Complex polymorphic system of gallic acid−five monohydrates, three anhydrates, and over 20 solvates, Cryst. Growth Des., 13, 19, 10.1021/cg301506x Heinz, 2009, Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy, J. Pharm. Pharmacol., 61, 971, 10.1211/jpp.61.08.0001 Taylor, 2000, Evaluation of solid-state forms present in tablets by Raman spectroscopy, J. Pharm. Sci., 89, 1342, 10.1002/1520-6017(200010)89:10<1342::AID-JPS12>3.0.CO;2-X Andrews, 2010, Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions, J. Pharm. Pharmacol., 62, 1580, 10.1111/j.2042-7158.2010.01177.x Lafi, 2012, Glass transition kinetics and crystallization mechanism in Se90Cd8Bi2 and Se90Cd6Bi4 chalcogenide glasses, J. Alloys. Compd., 519, 123, 10.1016/j.jallcom.2011.12.125 Imran, 2011, Crystallization kinetics, glass transition kinetics, and thermal stability of Se70-xGa30Inx (x=5, 10, 15, and 20) semiconducting glasses, Physica B Condens. Matter, 406, 482, 10.1016/j.physb.2010.11.019 Nehm, 2006, Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation, Cryst. Growth Des., 6, 592, 10.1021/cg0503346 Ren, 2021, Gelation of small molecule amorphous drugs, Acta Pharm. Sin., 56, 855 Abbiati, 2017, Enterohepatic circulation effect in physiologically based pharmacokinetic models: the sorafenib case, Ind. Eng. Chem. Res., 56, 3156, 10.1021/acs.iecr.6b03686 Terhaag, 1986, The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison, Int. J. Clin. Pharmacol. Ther., 24, 298